author-photo

Marta Caporale

University of Milan

47

Papers

493

Citations

Citation Trend

Filter By

Papers (34) Sort By

Journal Conference Others

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

2019 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (31)
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

2019 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (7)
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions

2017 Oncology
Show All
- Source
- Cite
- Save
Citations (5)
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (21)
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (20)
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis

2017 Journal of gastrointestinal oncology
Show All
- Source
- Cite
- Save
Citations (46)
Toward the molecular dissection of peritoneal pseudomyxoma

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (41)
D23Pharmacogenomic evaluation of single nucleotide polymorphisms associated with oxaliplatin-induced peripheral neuropathy: a preliminary study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activity

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)